Cronos Group Inc. (CRON) Earnings Call Transcript & Summary
February 27, 2025
Earnings Call Speaker Segments
Operator
operatorGood morning. I’m Antoine, and I’ll be serving as your conference operator for today. I’d like to welcome all of you to Cronos Group’s conference call covering fourth quarter and full year 2024 earnings. This call is being recorded today. Right now, I’d like to hand things over to Anna Shlimak, Chief Strategy Officer. Please go ahead.
Anna Shlimak
executiveThank you, Antoine, and thanks to everyone for being here today as we go through Cronos' financial and business results for full year 2024 and the fourth quarter. With me on the call are Mike Gorenstein, our Chairman, President, and CEO, and James Holm, our CFO. This morning Cronos put out a news release announcing our financial results, and it has been filed on our EDGAR and CEDAR profiles. That information, along with the prepared remarks, will also be posted under Investor Relations on our website. Before handing the call to Mike, I want to remind everyone that during this call we may make forward-looking statements and refer to non-GAAP financial measures. Such forward-looking statements rest on management's current expectations and assumptions, which are subject to risks and uncertainties that could cause actual results to differ materially from those projected in the forward-looking statements. The factors that could cause actual results to differ materially from expectations are detailed in our earnings materials and our SEC filings that are available on our website, and any forward-looking statements made during this call are qualified in their entirety by those materials. Information about non-GAAP financial measures, including reconciliations to U.S. GAAP, can also be found in the earnings materials that are available on our website. Lastly, throughout this conference call we will be making statements regarding market share information.
Anna Shlimak
executiveExcept where noted, every market share figure comes from Hifyre. We'll go through prepared remarks now, and after that we'll open things up for a question-and-answer session. So with that, I'll hand things over to Mike Gorenstein, Cronos' Chairman, President, and CEO.
Mike Gorenstein
executiveThank you, Anna, and good morning to all of you. When I came back as Cronos' CEO 3 years ago, we laid out ambitious objectives: deliver strong top-line growth, enhance margins, and bring our operating expenses to the right size. Today, I'm proud to report that those objectives are paying off and are visible across the company. With another quarter of solid results and our steadfast dedication to disciplined operating expenses, we're demonstrating our capacity to generate growth while improving efficiency throughout our business. Compared with a year earlier, we increased annual net revenue by 35%. Our adjusted gross margins nearly doubled, and we keep exercising discipline in how we manage our operating expenses. Our 2024 results are proof that our business is performing, and we remain the leader in the global cannabis industry when it comes to product innovation and exceptional quality. Supported by our strong balance sheet, we're in an outstanding position to capture future growth opportunities and to further reinforce our leadership in the markets we serve as we look ahead to 2025. During 2024, we put investment into GrowCo to expand its cultivation and production capabilities, so as to guarantee a consistent supply of high-quality cannabis at greater scale. That strategic step was intended to boost operational efficiency, lower costs, and optimize margins through the use of advanced growing techniques.
Mike Gorenstein
executiveWe’re really looking forward to that investment’s new supply becoming available so it can serve rising demand in the markets where we already operate, as well as new markets once they open up to us. I’m confident we’ve put ourselves in a stronger position to satisfy growing consumer demand, keep product quality high, and support our expanding lineup of brands and products in a careful, considered manner. Our GrowCo expansion is moving along nicely. During Q4, Health Canada approved changes to the site’s perimeter, and we anticipate completing construction of the expanded cultivation and processing facilities in Q2, with the first harvests and sales from that new area expected to start in the second half of 2025. Until the first sales occur from the expanded facility, we hold the option to buy as much as 80% of GrowCo’s total production. After expansion sales commence, Cronos will be able to purchase as much as 70% of total production from that facility. The GrowCo expansion puts us in position to benefit from Canadian domestic demand and will drive international growth opportunities in 2025. Over the past year, I’ve been extremely proud of the progress we’ve achieved in R&D, including product development and innovation. Cronos has made meaningful strides in cannabis genetics, with gains not only in new strains that align with consumer preferences but also in reaching higher cannabinoid yield levels.
Mike Gorenstein
executiveThis comes from years of work devoted to our breeding and tissue culture programs. Shoppers keep seeking a flower value proposition built around the price-potency equation, and our genetics help us satisfy that demand, which has cemented our standing as a top-performing flower brand in Canada and internationally. Now, on brand updates, I'm pleased to report that Spinach closed the year as the number one cannabis brand in Canada by market share, reinforcing its leadership position. That result is driven by its number one rankings in both edibles and flower, a number four spot in vapes, and a number seven in pre-rolls. Spinach's steady market share gains testify to our unwavering commitment to quality, innovation, and delivering differentiated products that resonate with consumers in the highly competitive Canadian adult-use market. In the gummy category, our industry-leading Sours products captured 23% market share in Q4, with five of the top 10 best-selling edibles in Canada all part of the Sours lineup. Our fully blasted Sours innovations, featuring 10 milligrams of THC per piece, have been particularly well-received by consumers. In Q4, we launched two new fully blasted products, Peach Orange and Strawberry Mango, as well as a new CBD Berry Variety Pack, which debuted in BC at the end of December.
Mike Gorenstein
executiveEvery variety pack has 30 gummies, and each gummy delivers 30 milligrams of CBD, across three flavors: Blue Raspberry Watermelon, Strawberry Mango, and Blueberry Acai. On top of that, our Lord Jones brand has achieved meaningful progress within chocolate, ending the year ranked as the third best-selling chocolate brand in Canada. We also introduced a new Lord Jones Chocolate Fusions flavor in January — Fudge Brownie — featuring an even ratio of CBN, CBD, and THC. Spinach keeps demonstrating its strength in flower, retaining the number one position for Q4 and the full year with 6% market share. That success comes from popular genetics such as GMO Cookies, Wedding Cake, Space Cake, and Sour Chem, offered across a range of sizes. Continued wins from our breeding program, along with GrowCo's operational excellence, have reinforced our leadership in this category, guaranteeing consistent delivery of quality products that meet consumer demand. Although Spinach delivered strong flower growth in 2024 and demand remains robust, we don't anticipate that growth persisting until the back half of 2025, when added supply from the GrowCo expansion comes online. To get ready for the next growth phase, we'll keep strategically allocating existing supply between Spinach in Canada and Peace Naturals internationally.
Mike Gorenstein
executiveDuring Q4, we launched Blue Monster pre-rolls beneath Sonique, a new brand for the Québec region. Sonique, our regional brand, is designed to address the particular tastes and requirements of the Québec marketplace, providing items that connect with the province's distinctive cannabis culture. Through its strategic approach, the brand makes sure it seizes the essence of market trends in Québec, merging local knowledge with outstanding product development to establish trust and loyalty among cannabis enthusiasts across the region. Our strategy has consistently been to build a portfolio of top-selling and disruptive branded products that we can introduce in new markets as cannabis regulations open up around the world. Spinach becoming the number one best-selling brand in Canada validates our strong capabilities, and we are only beginning to expand our winning portfolio of borderless products and bring them to markets globally. Now, turning to Israel, our team there delivered remarkable performance throughout Q4, with record volumes sold and the highest sales per quarter in 2024. Cronos Israel has built significant momentum throughout the year despite a very competitive market, with evolving dynamics including increased competition, tariff threats, declining patient growth, entrance of HMOs, and the ongoing Middle East conflict. Despite all this, the Peace Naturals brand and product portfolio continues to grow.
Mike Gorenstein
executiveWe revamped Peace Naturals' portfolio through a new pricing approach, featuring selected cultivars tailored to what our patients need. Throughout 2024, growth was driven by hero cultivars such as Wedding Cake and GMO, together with the adjustments we made to the portfolio. Based on pharmacy data gathered by Cronos, Peace Naturals closed out the year as the top flower brand in Israel holding 24% market share, while the brand's oil products finished as the fourth most popular brand with 9% market share. Our turnaround in this market makes me incredibly proud, and I look forward to bringing more quality products to market in 2025. On the international side, we've achieved meaningful progress in the markets we've entered, and we're excited about what lies ahead. Our Peace Naturals brand is building strong momentum in Germany and keeps growing. A major priority for us in 2025 is market penetration. We're confident in the momentum we're generating, particularly since we're delivering the same high-quality products that drove us to the number one flower position in Canada. With that foundation, we believe we can clearly win and are well-positioned to capture even greater market share in Germany and elsewhere. In a similar way, in the U.K., although it's still early days, we're already witnessing promising growth, with Peace Naturals and our enthusiasts excited about the significant potential for expansion in this emerging market.
Mike Gorenstein
executiveWhat we've achieved here really shows how dedicated we are to leading the cannabis sector worldwide. We closed out the year on a high note, and I take real pride in what we achieved across 2024. Cronos still holds the industry's most robust balance sheet, with $859 million in cash and cash equivalents, which strengthens our capacity to put money into growth, innovation, and expanding around the globe. Revenue rose substantially year over year in every quarter, which reflects our ongoing market growth and sales momentum. At this point, I'll hand things to James, who will take you through the fourth quarter financials.
James Holm
executiveThanks, Mike, and good morning to everyone. During 2024, our net revenue rose 35% compared with the prior year, reaching $117.6 million, helped by strong results in Canada and Israel, along with solid improvement across international markets. Operating expenses came down by $5 million relative to the previous year, Adjusted EBITDA rose 45% year-over-year, and operating cash flow improved by $61.7 million, turning positive at $18.8 million. Next I'll walk through our fourth quarter 2024 results, which now reflect consolidation of GrowCo's financials. Consolidated net revenue came in at $30.3 million, up 27% from the same period a year earlier. Cronos net revenue, excluding GrowCo, totaled $28.2 million, which represents 18% year-over-year growth on a standalone basis, while GrowCo contributed $2.1 million of net revenue in Q4 2024. The rise in net revenue was mainly attributable to greater cannabis flower and extract sales in Canada, plus higher flower sales in Israel and other countries. Fourth quarter gross profit was $10.8 million, equal to a 36% gross margin. Gross profit benefited from a $1.8 million adjustment tied to finalizing purchase accounting for the Cronos GrowCo transaction, which lowered the fair value of acquired inventory and the related inventory step-up previously recorded in Q3 cost of sales, producing adjusted gross profit of $9 million, or a 30% adjusted gross margin.
James Holm
executiveWe'll keep making that adjustment until the inventory that purchase accounting marked up to fair market values has been fully sold off, since we think it helps when reviewing and assessing how our ongoing performance is tracking. For full year 2024, adjusted gross profit on a year-over-year basis rose by $18.6 million, and adjusted gross margin climbed 12 percentage points to 26%, which nearly doubled the gross margin we posted in the prior year. That gain came mainly from greater sales of cannabis flower and extract in Canada, stronger cannabis flower sales in Israel, and improvements in production costs. Adjusted EBITDA for the fourth quarter came in at -$7.2 million, an improvement of $7.6 million compared with the prior year period. Higher revenue and increased adjusted gross profit drove that improvement. The disciplined approach we've taken to operating expenses so far let us realize $8.7 million in savings for 2024 compared with the prior year for Cronos on a standalone basis. With that, we hit the top end of the range in our previously announced guidance of a $5-$10 million reduction for standalone Cronos. Those operating expense savings came from cost cuts in general and administrative, research and development, and sales and marketing.
James Holm
executiveAs we head into 2025, we expect our OpEx to stay flat, even after factoring in GrowCo's OpEx. Also, our reported CapEx includes the facility expansion at GrowCo that we announced earlier — something to keep in mind as you look toward 2025. Moving to the balance sheet and cash flow statement, the company finished the quarter with $859 million in cash and cash equivalents. That cash and cash equivalents figure was down $3 million from Q3 2024, mainly because of $3.7 million in CapEx spend in Q4 2024 and FX fluctuations, partly offset by $7.7 million in cash from operations in 2024. For the full year, capital expenditure rose $9.7 million year-over-year, reflecting investments at our GrowCo facility and better automation capabilities at our Peace Naturals campus in Stayner. In 2024, we brought in $18.8 million of cash from operating activities, versus 2023, when cash used was $42.8 million — an increase in cash flow from operating activities of $61.7 million. That change came mainly from a $32.8 million tax payment made in 2023, tied to the previously disclosed relinquishment by Altria of its warrant to purchase additional shares of the company in 2022, a $38.8 million increase in net income after adjusting for non-cash items during 2024 compared to 2023, and higher interest received.
James Holm
executiveSo free cash flow in Q4 2024 came in at plus $4 million, versus plus $15 million in the same period a year earlier. For the whole of 2024, free cash flow was a positive $5.7, against negative $46.3 million for all of 2023 — that works out to a $51.9 million improvement. Our cash balance remains steady, and as you can see, the underlying fundamentals of our operations are improving significantly. Reflecting on how far we've come, I echo Mike's confidence in where the business is headed and in how ready we are to enter new markets as they open up. With that, I'd like to turn it back to Mike for a brief remark before we move to Q&A.
Mike Gorenstein
executiveOver the course of this year, we delivered strong results in every quarter, fueled by solid revenue gains, better margins, and rigorous cost control. We strengthened our market leadership in Canada and Israel, hit major milestones in international markets, and kept innovating through new product launches. With a strong balance sheet and a clear strategic focus, Cronos is well-positioned to capitalize on future growth opportunities and enhance our position in the global cannabis industry. Looking ahead, we remain focused on innovation, operational excellence, and strategic expansion. Our core business is performing exceptionally well, and we are well-positioned to capitalize on the growing global cannabis market as we look forward to 2025. With that, I'll open the line for questions.
Operator
operatorThanks. We’re going to open it up for questions now. Just a reminder: if you’d like to ask something, press star one one on your phone and hang on until your name is called. If you want to take your question back, just hit star one one a second time. Please hold while we put together the Q&A list. Right now I’m not seeing any questions. Thanks for joining today’s conference. That brings the program to a close. You can disconnect at this point.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Cronos Group Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Cronos Group Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Cronos Group Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.